(Q46099532)

English

Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article published on 5 March 2009

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Mitsune Tanimoto

17

object named as

Mitsune Tanimoto

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Atae Utsunomiya

11

object named as

Atae Utsunomiya

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

9

object named as

Noriko Usui

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

author name string

Hisashi Sakamaki

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Ken-ichi Ishizawa

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Masafumi Taniwaki

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Shin Fujisawa

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Yasuo Morishima

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Kensei Tobinai

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Masaya Okada

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Kiyoshi Ando

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Shuichi Miyawaki

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Nobuhiko Uoshima

12

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Tadashi Nagai

13

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Tomoki Naoe

14

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Toshiko Motoji

15

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Itsuro Jinnai

16

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Yasushi Miyazaki

18

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Kazunori Ohnishi

19

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Shinsuke Iida

20

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Shinichiro Okamoto

21

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Taku Seriu

22

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Ryuzo Ohno

23

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

publication date

5 March 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

89

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

332-341

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The BCR-ABL story: bench to bedside and back

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical resistance to imatinib: mechanisms and implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19263190

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-009-0260-2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19263190

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46099532&oldid=2207631975"